Sagar Lonial MD (@sagarlonialmd) ranks #20 among US multiple myeloma KOLs on X in 2026, by engagement from fellow physicians. 7 physicians shared, quoted or replied to Dr. Lonial's posts this year. Fellow physicians posted about Dr. Lonial's IMS 2026 late-breaking abstracts (3 physicians). CMS Open Payments lists $649,007 in 2025 general payments.
At a Glance
- Multiple Myeloma: US #20, Global #25 · 7 physicians engaged
- Presented at IMS 2026, ASH 2025 in 2026
- CMS Open Payments lists $649,007 in 2025 general payments.
This Month
What Sagar Lonial MD has posted in the last 30 days. Updated November 13, 2026.
No trial posts in the last 30 days.
2026 Rankings
| List | US rank | Global rank | Peer Engagement Score | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|---|
| Multiple Myeloma | #20 | #25 | 42/100 | 7 | 12 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Sagar Lonial MD presented at IMS 2026 and ASH 2025, each confirmed by a public source.
- IMS 2026 · Late-breaking abstractEXCALIBER-RRMM: IberDd vs DVd in RRMM (LBA-12)
- IMS 2026 · Late-breaking abstractFirst results of phase 3 EXCALIBER-RRMM (IberDd vs DVd)EXCALIBER-RRMM trial profile → · Source: @MM_Hub on X ↗
- ASH 2025 · PosterExploratory overall quality of life in DREAMM-7 (abstract 4029)
What Colleagues Are Saying About Sagar Lonial MD
2026 posts by fellow physicians that mention @sagarlonialmd, quoted word for word.
Iberdomide (CELMoD) + Dara is now @US_FDA ✅ in 2L and beyond for MM off EXCALIBER-RRMM! We 🗣️ this trial, findings (MRD), and AEs w/ @SagarLonialMD Full 🗣️: ⭐️ https://t.co/Yz22UshNVx ⭐️Also on “Oncology Brothers” podcast @OncUpdates #OncTwitter #HemeTwitter https://t.co/T62CkU7ANI
#IMS26 @SagarLonialMD presenting EXCALIBER-RRMM. Finally, the Iber-Dd CELMoD data we've been eagerly awaiting! Rationale for presenting now, he just explained: Request from 🇺🇸 FDA not to release MRD-CR-based data before their formal approval. This is why I attend conferences! https://t.co/ub3NWs6xtH
EXCALIBER-RRMM (Iberdomide-Dd vs DVd) by @SagarLonialMD 🏆#IMS26: EXCALIBER-RRMM: IberDd doubles MRD-neg CR vs DVd in 420 pts (40% vs 20%, P<0.0001). 💡Non-Heme AE: Diarrhea 30%, fatigue 25%, rash 10%, mostly G1, seemingly better than Len based combinations 💡Gr3+ neutropenia https://t.co/vjD9YDbW5G
Industry Payments
CMS Open Payments · 2025 general payments
$649,007 across 16 payments